Terumo Blood and Cell Technologies' IMUGARD Platelet Pooling Set Cleared by FDA

Rhea-AI Summary

Terumo Blood and Cell Technologies has received FDA clearance for its IMUGARD® WB Platelet Pooling Set, which extends the shelf life of whole blood-derived platelets from five days to seven days. This innovation aims to address the increasing demand for platelets amid a declining supply due to the shortage of blood donors. In the U.S., over 2.5 million units of platelets were transfused in 2021. The IMUGARD system provides an alternative source for blood centers to manage platelet supply effectively and reduce waste, benefitting patients in need of transfusions.

Positive

• FDA clearance of IMUGARD® WB Platelet Pooling Set enhances platelet supply management.
• Increases shelf life of platelets from 5 days to 7 days, providing greater flexibility.
• Addresses platelet supply challenges amid rising demand and donor shortages.

Negative

• None.

IMUGARD to Help Strained U.S. Platelet Supply Meet Growing Need

LAKEWOOD, Colo., Feb. 16, 2023 /PRNewswire/ -- Today, Terumo Blood and Cell Technologies announces U.S. Food and Drug Administration (FDA) clearance and official launch of its IMUGARD^® WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days.^[1] IMUGARD is the first platelet pooling set approved for seven-day storage in the U.S. and provides an alternate source of platelet supply at a time when demand continues to increase while the supply remains challenged by the lack of blood donors.

Terumo Blood and Cell Technologies is a medical technology company that makes products that collect, process and separate blood and cells. Platelets are a component of human blood that form clots and stop bleeding. They are used to treat many different patients, such as those undergoing chemotherapy, organ transplants and bone marrow transplants. In 2021, more than 2.5 million units of platelets were transfused in the U.S., up from 2.3 million in 2019, according to the National Blood Collection and Utilization Survey (NBCUS).

Terumo Blood and Cell Technologies' latest innovation aims to increase the availability of platelets for transfusion. IMUGARD enables extended shelf life of platelets from the standard five days to seven days.^[1] This can help blood centers better manage supply to meet patient needs and reduce waste.^[2,3]

Most of the platelets in the United States are currently collected by apheresis. IMUGARD now gives blood centers another product choice to help them recoup platelets from whole blood donations.

"We continue to invest in innovations that help blood centers to positively impact patients," says Chetan Makam, General Manager, Global Blood Solutions, Terumo Blood and Cell Technologies. "IMUGARD opens the possibility for U.S. blood centers to use the platelets from their whole blood donations to increase the number of platelets available for transfusion. We are the first company to provide seven-day shelf life of both apheresis and whole blood-derived platelets in the U.S., adding flexibility to the platelet supply. This is especially important now with the increased demand for platelets and the challenges blood centers face with recruiting new apheresis platelet donors."

About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

[1] U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion. December 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-risk-control-strategies-blood-collection-establishments-and-transfusion-services-enhance.

[2] Delage G, Bernier F, Beaudoin J, Thibault S, Dion J, Gagné L. Improved bacterial culture of platelet product: preliminary results after implementation of a two-bottle system with 48-hour sampling. Transfusion. 2016:56(S4);28A.

[3] Harm SK, Szczepiorkowski ZM, Dunbar NM. Routine use of Day 6 and Day 7 platelets with rapid testing: two hospitals assess impact 1 year after implementation. Transfusion. 2018;58(4):938-942.

 

IMUGARD^® WB PLT Platelet Pooling Set

IMUGARD is the first platelet pooling set approved for seven-day storage in the U.S.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-blood-and-cell-technologies-imugard-platelet-pooling-set-cleared-by-fda-301749297.html

SOURCE Terumo Blood and Cell Technologies

FAQ

What is the IMUGARD® WB Platelet Pooling Set and its significance for TRUMY?

The IMUGARD® WB Platelet Pooling Set by Terumo Blood and Cell Technologies extends the shelf life of whole blood-derived platelets from 5 to 7 days, addressing supply challenges in the U.S.

When did Terumo Blood and Cell Technologies receive FDA clearance for IMUGARD?

The FDA clearance for the IMUGARD® WB Platelet Pooling Set was granted on February 16, 2023.

How does IMUGARD impact platelet transfusion rates in the U.S.?

IMUGARD aims to increase the availability of platelets for transfusion, which is crucial as over 2.5 million units were transfused in 2021.

What are the implications of IMUGARD for blood centers in the U.S.?

IMUGARD provides blood centers with a new option to recoup platelets from whole blood donations, enhancing supply management.